228 related articles for article (PubMed ID: 26931184)
1. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
3. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
8. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
11. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
12. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
14. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
15. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
[TBL] [Abstract][Full Text] [Related]
16. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
17. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma.
Hasegawa M; Takata M; Hatta N; Wakamatsu K; Ito S; Takehara K
Melanoma Res; 1997 Jun; 7(3):243-51. PubMed ID: 9195564
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma.
Meyer T; Hauschild A; Kromminga A; Hartleb J; Arndt R; Christophers E; Stockfleth E
Melanoma Res; 2002 Oct; 12(5):471-7. PubMed ID: 12394189
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
